On November 15 last year we advised our readers that CMS had initiated an ill-advised process to “discourage the use of PSA-based screening” for prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: CMS, risk, screening, testing | 1 Comment »
Apparently our friends at the Centers for Medicare and Medicaid Services (CMS) have misunderstood the details of the D recommendation about PSA screening for prostate cancer issued by the U.S. Preventive Services Task Force (USPSTF) in 2012, … READ MORE …
Filed under: Diagnosis, Risk | Tagged: CMS, Medicare, policy, PSA, screening | 4 Comments »
As many in the prostate cancer community will be aware, there has been a major battle ongoing over whether the drug bevacizumab (Avastin) should continue to be approved by the U.S. Food & Drug Administration (FDA) for the treatment of women with metastatic breast cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Centers for Medicare and Medicaid Services, CMS, coverage, off-label | Leave a comment »
The Centers for Medicare and Medicaid Services (CMS) proposed yesterday that there is sufficient and adequate evidence to conclude that the use of autologous cellular immunotherapy treatment — sipuleucel-T (Provenge®) — improves health outcomes for Medicare beneficiaries … READ MORE …
Filed under: Management, Treatment | Tagged: CMS, coverage, Medicare, Provenge, sipuleucel-T | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 